| Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after … YK Barqawi, ME Borrego, MH Roberts, I Abraham Journal of medical economics 22 (11), 1202-1209, 2019 | 29 | 2019 |
| Novel oral anticoagulants and the 73rd anniversary of historical warfarin A Shehab, AA Elnour, AS Bhagavathula, P Erkekoglu, F Hamad, ... Journal of the Saudi Heart Association 28 (1), 31-45, 2016 | 28 | 2016 |
| Community–clinical linkages: The effects of the Healthy Here Wellness Referral Center on chronic disease indicators among underserved populations in New Mexico TH Cruz, B Boursaw, YK Barqawi, CA FitzGerald, N Enoah, A Hayes, ... Health promotion practice 23 (1_suppl), 164S-173S, 2022 | 3 | 2022 |
| Immune-Mediated and Psychiatric Comorbidities Among Patients Newly Diagnosed With Alopecia Areata A Mostaghimi, AM Soliman, C Li, YK Barqawi, A Grada JAMA dermatology 160 (9), 945-952, 2024 | 1 | 2024 |
| Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy MH Roberts, MY Takeda, S Kindilien, YK Barqawi, ME Borrego Expert review of pharmacoeconomics & outcomes research 18 (5), 487-503, 2018 | 1 | 2018 |
| Cost Effectiveness Analysis of Enzalutamide, Abiraterone Plus Prednisone and Cabazitaxel Plus Predinsone for the Treatment of Visceral Metastatic Castration Resistant Prostate … YK Barqawi | 1 | 2018 |
| HSD19 Longitudinal Changes in Metabolic Syndrome Risk Factors (MSRF) Screening and Treatment Rates Between 2010 and 2021 Among Patients With Prostate Cancer (PCa) Treated With … M Borrego, Y Barqawi, M Roberts, T Thompson, N Hashemi Value in Health 27 (12), S329-S330, 2024 | | 2024 |
| Cost-Offset Analysis Performed Utilizing Covalent Bruton's Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia AS Kittai, DA Patel, J Shafrin, N Zawadzki, V Shetty, K Sharma, ... Blood 144, 5031, 2024 | | 2024 |
| 50629 Impact of Achieving F-VASI 75 or T-VASI 50 on Patient-and Physician-Reported Outcomes in Patients With Non-Segmental Vitiligo (NSV) Receiving Upadacitinib During a Phase … D Rosmarin, AM Soliman, YK Barqawi, C Li, BJ Schlosser, K Ezzedine Journal of the American Academy of Dermatology 91 (3), AB52, 2024 | | 2024 |
| Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data B Strober, AM Soliman, B Truong, MB Patel, YK Barqawi, P Gisondi American Journal of Clinical Dermatology 25 (5), 853-856, 2024 | | 2024 |
| Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation … YK Barqawi, ME Borrego, MH Roberts, T Thompson, N Hashemi-Sadraei Journal of Clinical Oncology 42 (4_suppl), 29-29, 2024 | | 2024 |
| Racial and Ethnic Differences in the Receipt of Metabolic Syndrome Risk Factor Screening and Treatment Among Prostate Cancer Patients Treated With Androgen Deprivation Therapy YK Barqawi The University of New Mexico, 2022 | | 2022 |
| PCN101 COST EFFECTIVENESS ANALYSIS COMPARING ENZALUTAMIDE, ABIRATERONE PLUS PREDNISONE AND CABAZITAXEL PLUS PREDINSONE FOR THE TREATMENT OF VISCERAL METASTATIC CASTRATION … Y Barqawi, M Borrego, M Roberts, I Abraham Value in Health 22, S75, 2019 | | 2019 |
Matthew E BorregoUniversity of New Mexico College of Pharmacy在 salud.unm.edu 的电子邮件经过验证
